LMO3

LMO3 is a nuclear LIM-only transcriptional scaffold that lacks intrinsic DNA-binding activity and instead modulates gene expression by assembling protein–protein complexes with diverse transcription factors and signaling kinases. In neuroblastoma, LMO3 forms a complex with the bHLH factor HEN2 that sequesters the repressor HES1 away from the Mash1 promoter, de-repressing Mash1 transcription and promoting tumor growth (PMID:15930276, PMID:21573214); LMO3 also directly binds the p53 DNA-binding domain and co-represses p53-dependent transcription without blocking p53 chromatin occupancy (PMID:19995558). Beyond neural cancers, LMO3 functions as a human-specific glucocorticoid-induced regulator of PPARγ-dependent adipogenesis (PMID:23823477), and in hepatocellular carcinoma it suppresses Hippo signaling by interacting with the kinase LATS1 to block YAP phosphorylation, thereby driving invasion and anoikis resistance (PMID:30219064). Lmo3-null mice are viable due to functional redundancy with Lmo1, but compound Lmo1/Lmo3 double-null mice die perinatally, establishing an essential shared developmental role (PMID:14966285).

1. 1997 Medium

   Establishing that LMO3 is expressed in specific neuronal populations in the adult brain and is dynamically regulated by neural activity resolved where this LIM-only gene operates in the CNS.

   Evidence In situ hybridization and immunohistochemistry in mouse brain with kainic acid seizure model

   PMID:9204936

   Open questions at the time

   • Downstream transcriptional targets in neurons remain unidentified
   • Functional consequence of seizure-induced LMO3 downregulation is unknown
2. 2004 High

   Demonstrating that Lmo3-null mice are phenotypically normal but Lmo1/Lmo3 double-null mice die perinatally established functional redundancy between LMO1 and LMO3 during development and revealed an essential collective role.

   Evidence Gene-targeted knockout mice; compound Lmo1/Lmo3 double-null phenotypic analysis

   PMID:14966285

   Open questions at the time

   • Specific cell types or developmental processes requiring LMO1/LMO3 not identified
   • Whether LMO3 and LMO1 share the same protein partners in embryogenesis is unknown
3. 2005 High

   Identifying LMO3 as a nuclear interactor of HEN2 that promotes neuroblastoma growth and tumorigenesis established LMO3 as an oncogene and defined its first binding partner.

   Evidence Co-immunoprecipitation, immunostaining, stable overexpression in SH-SY5Y cells, soft-agar assay, and nude-mouse xenograft

   PMID:15930276

   Open questions at the time

   • Transcriptional targets downstream of the LMO3/HEN2 complex were not identified
   • The domain(s) of LMO3 required for HEN2 binding were not mapped
4. 2009 High

   Showing that LMO3 directly binds the p53 DNA-binding domain and co-represses p53 target gene transcription — without blocking p53 chromatin occupancy — revealed a second transcription-factor partner and an unexpected co-repressor mechanism.

   Evidence In vitro binding, co-immunoprecipitation, ChIP, and luciferase reporter assays

   PMID:19995558

   Open questions at the time

   • The co-repressor mechanism (e.g., recruited histone modifiers) is not defined
   • Whether p53 co-repression contributes to neuroblastoma oncogenesis in vivo is untested
5. 2011 High

   Elucidating that the LMO3/HEN2 complex displaces the repressor HES1 from the Mash1 promoter to de-repress Mash1 transcription provided the first complete mechanistic circuit for LMO3-driven neuroblastoma gene regulation.

   Evidence ChIP, luciferase reporter, co-immunoprecipitation, and siRNA knockdown in SH-SY5Y cells

   PMID:21573214

   Open questions at the time

   • Whether Mash1 is the sole or primary oncogenic effector downstream of LMO3/HEN2 is unclear
   • Structural basis for HES1 displacement by the LMO3/HEN2 complex is unknown
6. 2013 High

   Identifying LMO3 as a direct NKX2-1/FOXA1 transcriptional target required for survival in NKX2-1-amplified lung adenocarcinoma, and independently as a glucocorticoid-induced human-specific driver of PPARγ-dependent adipogenesis, broadened LMO3 function beyond neuroblastoma to distinct tissue contexts.

   Evidence ChIP-seq cistromics with RNAi survival assays in lung cancer lines; GR pathway analysis with gain/loss-of-function in human adipose stromal cells

   PMID:23322301 PMID:23823477

   Open questions at the time

   • Direct transcriptional targets of LMO3 in adipocytes and lung cancer cells are not defined
   • Protein partners mediating LMO3 action in adipogenesis are unknown
   • Why LMO3 adipogenic function is absent in mouse remains unexplained
7. 2015 Medium

   Demonstrating that miR-630 directly targets LMO3 mRNA in NSCLC and that miR-101 indirectly suppresses LMO3 via epigenetic remodeling of its promoter in glioma established upstream regulatory layers controlling LMO3 expression in cancers.

   Evidence Luciferase 3′-UTR reporter with rescue experiments (miR-630/NSCLC); MeDIP-Chip and ChIP for histone marks (miR-101/glioma)

   PMID:25829251 PMID:26328011

   Open questions at the time

   • Single-lab findings for each miRNA; independent replication lacking
   • Whether these miRNAs regulate LMO3 in non-cancer contexts is untested
8. 2018 High

   Identifying LMO3 as a direct LATS1 interactor that suppresses Hippo/YAP signaling in HCC, and as an activator of Akt/mTOR/GSK3β signaling in gastric cancer, revealed that LMO3 scaffolding extends to cytoplasmic kinase pathways beyond classical transcriptional regulation.

   Evidence Co-immunoprecipitation of LMO3–LATS1, recombinant protein rescue, pharmacological inhibitors of mTOR and GSK3β in functional assays, in vivo metastasis model

   PMID:29436606 PMID:30219064

   Open questions at the time

   • How a nuclear LIM-only protein accesses cytoplasmic LATS1 is mechanistically unexplained
   • Direct versus indirect activation of Akt by LMO3 is not resolved
   • Gastric cancer pathway findings are from a single lab without independent confirmation

• Key unresolved questions include the structural basis for LMO3 partner selectivity across tissues, the identity of direct transcriptional targets beyond Mash1, and whether the cytoplasmic kinase interactions (LATS1, Akt) require shuttling or are mediated by distinct LMO3 pools.
• No crystal or cryo-EM structure of LMO3 in complex with any partner
• Genome-wide direct target identification (e.g., CUT&RUN for LMO3-containing complexes) has not been performed
• Nuclear–cytoplasmic distribution and shuttling of LMO3 have not been systematically characterized